Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408843 | 0.88 | MAPT (0.83) | MAPTSMN1; SMN2CYP19A1ALDH1A1POLB | |
| SCHEMBL24969427 | 0.86 | MAPT (0.69) | MAPTCYP19A1ALDH1A1POLBHPGD | |
| SCHEMBL10165811 | 0.83 | SMN1; SMN2 (0.62) | MAPTSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL12952780 | 0.83 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2LMNAHTTMEN1 | |
| SCHEMBL10557875 | 0.83 | MAPT (0.75) | MAPTSMN1; SMN2CYP19A1ALDH1A1POLB | |
| SCHEMBL11608031 | 0.83 | MAPT (0.75) | MAPTSMN1; SMN2CYP19A1ALDH1A1POLB | |
| SCHEMBL15094106 | 0.82 | MAPT (0.52) | MAPTCYP19A1ALDH1A1HPGDMEN1 | |
| SCHEMBL626949 | 0.81 | MAPT (0.73) | MAPTSMN1; SMN2CYP19A1ALDH1A1POLB | |
| SCHEMBL26818503 | 0.81 | MAPT (0.55) | MAPTSMN1; SMN2LMNACYP19A1ALDH1A1 | |
| SCHEMBL9977891 | 0.80 | MAPT (0.71) | MAPTSMN1; SMN2LMNACYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
| US-8383829-B2 | Electrochromic compound, electrode, and display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20090256121-A1 | ELECTROCHROMIC COMPOUND, ELECTRODE, AND DISPLAY ELEMENT | KONICA MINOLTA HOLDINGS, INC. (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | MAPT 989/4885SMN1; SMN2 866/4885LMNA 215/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | MAPT 989/4885SMN1; SMN2 866/4885LMNA 215/4885 |
| US-20090256121-A1 | ELECTROCHROMIC COMPOUND, ELECTRODE, AND DISPLAY ELEMENT | SCN11A, HCN2, RER1 | MAPT 4552/4885SMN1; SMN2 2317/4885LMNA 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.